Radioligand therapy with 177Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use.
about
Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095.177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer.Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy.The synergy between ionizing radiation and immunotherapy in the treatment of prostate cancer.
P2860
Radioligand therapy with 177Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Radioligand therapy with 177Lu ...... been arrived in clinical use.
@en
Radioligand therapy with 177Lu ...... been arrived in clinical use.
@nl
type
label
Radioligand therapy with 177Lu ...... been arrived in clinical use.
@en
Radioligand therapy with 177Lu ...... been arrived in clinical use.
@nl
prefLabel
Radioligand therapy with 177Lu ...... been arrived in clinical use.
@en
Radioligand therapy with 177Lu ...... been arrived in clinical use.
@nl
P1476
Radioligand therapy with 177Lu ...... been arrived in clinical use.
@en
P2093
Markus Essler
Michael Schäfers
P356
10.1016/J.NUCMEDBIO.2016.08.003
P577
2016-08-13T00:00:00Z